Glucagon-Like Peptide 1 – Page 7 – Talk Bio

Actionable Insights Powered by AI

Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###

1 year ago talkbio0Tagged alpha 1-antitrypsin, Diabetes, Eli, Eli Lilly, Glucagon-Like Peptide 1, Indiana, Manufacture, Mounjaro, Nordisk, Obesity, Zepbound

Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs

Hims & Hers Expands Weight-Loss Solutions with GLP-1 Injections

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Hims & Hers, Injection of therapeutic agent, metabolic health, Obesity, Prescription procedure, Telemedicine, Weight-Loss

Hims & Hers, GLP-1 injections, weight-loss, telehealth, prescription medication, obesity treatment, metabolic health

EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts

1 year ago talkbio0Tagged European Medicines Agency, Evaluation, Feeling suicidal (finding), Glucagon-Like Peptide 1, Ozempic, Wegovy

GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation

Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs

1 year ago talkbio0Tagged Glucagon-Like Peptide 1, Health Care Costs, liraglutide, Lower prescription rates, Medicare, Mounjaro, Obesity, Saxenda, semaglutide, tirzepatide, Truveta study, Wegovy

GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study